Table 3

Treatment, Follow-Up, and Prognosis of Recently Reported Xp11.2 Translocation Renal Cell Carcinomas in Patients Aged 16 or Older

Treatment

Pattern of Progression


Source, Year

Pts, No.

Age, y/Sex

Primary Treatment

Additional Treatment

Local Recurrence

Metastases

Follow-Up Time, y

Outcome


Dal Cin et al, 1998 [10]

1

53/F

RN

Resection of metastases

None

Lung, bone, liver, adrenal, retroperitoneal LNs

31

NS


Salles and Soto, 2005 [11]

1

58/F

RN

None

None

Renal hilar LNs

0.5

FOD


Mansouri et al, 2006 [12]

1

16/F

RN

Resection of metastases, ChemoRx, IFN-α, IL-2

Yes

Lung, bone, adrenal, lumbar-aortic LNs

NS

NS


Schinstine et al, 2006 [13]

1

57/F

RN

Resection of metastases

None

Lung

1

NS


Meyer et al, 2007 [14]

5

32.6 (mean)/5M

4 RN; 1 renal Bx

Resection of metastases, ChemoRx, XRT, IL-2, investigational agents

Yes

Lung, bone, liver, brain, mediastinal LNs

1.5 (mean)

2 DOD


Rais-Bahrami et al, 2007 [15]

1

23/M

RN

Resection of metastases, ChemoRx, investigational agents

None

Lung, liver, retroperitoneal, supraclavicular, cervical and mediastinal LNs

17

DOD


Suzigan et al, 2007 [16]

1

17/F

PN

None

None

None

0.33

FOD


Argani et al, 2007 [17]

28

22–68 (range)/22F, 6M

NS

NS

NS

5 hematogenous metastases

NS

2 DOD


Armah and Parwani, 2008 [18]

1

33/M

RN

Resection of metastases, ChemoRx, XRT, IFN-α, IL-2

None

Lung, liver, bone, brain, mediastinal LNs

0.58

DOD


Camparo et al, 2008 [19]

31

24.6 (mean)/18F, 13M

30 RN; 1 renal Bx

Resection of metastases, ChemoRx, XRT, IFN-α, IL-2, investigational agents

NS

Lung, liver, bone, LNs

0.5–7.67 (range)

5 DOD


Wu et al, 2008 [9]

3

17–20 (range)/1F, 2M

3RN

Resection of metastases, investigational agents

Yes

Retroperitoneal LNs

1.7–3.4 (range)

1 DOD


Gellar et al, 2008 [20]

4

16–17 (range)/3F, 1M

4RN

ChemoRx, IFN-α, IL-2, investigational agents

None

Lung, liver

1.17–15.42 (range)

1 DOD


Hintzy et al, 2008 [21]

6

28–42 (range)/4F, 2M

NS

NS

NS

3 hematogenous metastases

2.67 (mean)

1 DOD


Komai et al, 2009 [22]

6

24–59 (range)/2F, 4M

6RN

Resection of metastases, IFN-α, IL-2

None

Lung, liver, LNs

0.75–11 (range)

2 DOD


Bovio et al, 2009 [23]

1

20/F

RN

NS

None

Placenta, bone, retroperitoneal LNs

2

NS


Koie et al, 2009 [24]

1

28/M

RN

Resection of metastases, IFN-α, IL-2

Yes

Lung, liver, adrenal, spleen, pancreas, psoas muscle, mesentery, descending colon, retroperitoneal LNs

2

DOD


Bx, biopsy; ChemoRx, chemotherapy; DOD, died of disease; F, female; FOD, free of disease; IFN-α, interferon-α; IL-2, interleukin-2; LNs, lymph nodes; M, male; No., number; NS, not specified; PN, partial nephrectomy; Pts, patients; RN, radical nephrectomy; XRT, radiotherapy; y, years

Armah et al. Diagnostic Pathology 2009 4:15   doi:10.1186/1746-1596-4-15

Open Data